| pubmed-article:2709372 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2709372 | lifeskim:mentions | umls-concept:C0023418 | lld:lifeskim |
| pubmed-article:2709372 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:2709372 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:2709372 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:2709372 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:2709372 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:2709372 | pubmed:dateCreated | 1989-6-6 | lld:pubmed |
| pubmed-article:2709372 | pubmed:abstractText | Two previously synthesized and two structurally novel thiazoline iron chelators are described. N4-Benzyl-N1,N8-bis[[2-(2-hydroxyphenyl)thiazolin-4-yl]carbonyl] homospermidine (5) proved to be the most potent antiproliferative and cytocidal compound in the series with in vitro IC50 values of 3 and 1 microM on L1210 and P388 murine cell lines. The N4-acetyl analogue 7 was considerably less active than 5 with IC50 and cell viability values that were similar to those of the structurally simple thiazolines 2 and 3. The antiproliferative activity of 3 and 7 could be substantially reduced or ablated by delivery to cell suspensions as a 1:1 molar mixture with FeCl3, while the activity of 5 was unaffected by Fe(III) chelation. As expected, 3 induced a G1/S cell cycle block at the 100 microM block consistent with interference with DNA synthesis while 10 microM 5 did not affect L1210 cell cycle distribution. Tritiated thymidine incorporation studies confirmed that 5 was incapable of interfering with DNA synthesis at concentrations below 40 microM. Alkaline elution studies indicate that 5 does not cause DNA strand breaks in vitro at concentrations of 10 microM. The N4-benzyl group of 5 appears to impart in vitro potency as the N4-acetyl analogue 7 lacks comparable in vitro antiproliferative and cytocidal activity. | lld:pubmed |
| pubmed-article:2709372 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2709372 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2709372 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2709372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2709372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2709372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2709372 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2709372 | pubmed:month | May | lld:pubmed |
| pubmed-article:2709372 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:2709372 | pubmed:author | pubmed-author:NagleW AWA | lld:pubmed |
| pubmed-article:2709372 | pubmed:author | pubmed-author:BurnsE RER | lld:pubmed |
| pubmed-article:2709372 | pubmed:author | pubmed-author:KellyK FKF | lld:pubmed |
| pubmed-article:2709372 | pubmed:author | pubmed-author:ElliottG TGT | lld:pubmed |
| pubmed-article:2709372 | pubmed:author | pubmed-author:McColloughDD | lld:pubmed |
| pubmed-article:2709372 | pubmed:author | pubmed-author:BonaR LRL | lld:pubmed |
| pubmed-article:2709372 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2709372 | pubmed:volume | 32 | lld:pubmed |
| pubmed-article:2709372 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2709372 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2709372 | pubmed:pagination | 1039-43 | lld:pubmed |
| pubmed-article:2709372 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2709372 | pubmed:meshHeading | pubmed-meshheading:2709372-... | lld:pubmed |
| pubmed-article:2709372 | pubmed:meshHeading | pubmed-meshheading:2709372-... | lld:pubmed |
| pubmed-article:2709372 | pubmed:meshHeading | pubmed-meshheading:2709372-... | lld:pubmed |
| pubmed-article:2709372 | pubmed:meshHeading | pubmed-meshheading:2709372-... | lld:pubmed |
| pubmed-article:2709372 | pubmed:meshHeading | pubmed-meshheading:2709372-... | lld:pubmed |
| pubmed-article:2709372 | pubmed:meshHeading | pubmed-meshheading:2709372-... | lld:pubmed |
| pubmed-article:2709372 | pubmed:meshHeading | pubmed-meshheading:2709372-... | lld:pubmed |
| pubmed-article:2709372 | pubmed:meshHeading | pubmed-meshheading:2709372-... | lld:pubmed |
| pubmed-article:2709372 | pubmed:meshHeading | pubmed-meshheading:2709372-... | lld:pubmed |
| pubmed-article:2709372 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2709372 | pubmed:articleTitle | In vitro antiproliferative activity of 4-substituted 2-(2-hydroxyphenyl)thiazolines on murine leukemia cells. | lld:pubmed |
| pubmed-article:2709372 | pubmed:affiliation | Ribi ImmunoChem Research, Inc., Hamilton, Montana 59840. | lld:pubmed |
| pubmed-article:2709372 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2709372 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:2709372 | lld:chembl |
